Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic

Nat Med. 2019 Apr;25(4):547-553. doi: 10.1038/s41591-019-0412-8. Epub 2019 Apr 1.


Combination anti-retroviral therapy (ART) has revolutionized the treatment and prevention of HIV-1 infection. Taken daily, ART prevents and suppresses the infection. However, ART interruption almost invariably leads to rebound viremia in infected individuals due to a long-lived latent reservoir of integrated proviruses. Therefore, ART must be administered on a life-long basis. Here we review recent preclinical and clinical studies suggesting that immunotherapy may be an alternative or an adjuvant to ART because, in addition to preventing new infections, anti-HIV-1 antibodies clear the virus, directly kill infected cells and produce immune complexes that can enhance host immunity to the virus.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Neutralizing / therapeutic use*
  • Clinical Trials as Topic
  • HIV Antibodies / therapeutic use*
  • HIV Infections / drug therapy*
  • HIV Infections / immunology*
  • HIV Infections / prevention & control
  • HIV-1 / immunology*
  • Humans


  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • HIV Antibodies